The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas

Diagnostic Pathology

Chengshi Quan¹  Xueyan Dong²  Xiaowei Zhang²  Ting Zhang²  Zhijing Liu²  Lina Yu²  Yaxiong Guo²  Qiong Wu³  Li Liu⁵  Yafang Liu⁴  Huiying Jin⁵  Xiaoming Xu² 

[1] The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical College, Jilin University, 126 Xinmin street, Changchun, Jilin 130021, People's Republic of China;The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical College, Jilin University, Changchun, Jilin, China;Department of Pathology, The Third Bethune Hospital of Jilin University, Changchun, Jilin, China;Department of Pathology, The First Bethune Hospital of Jilin University, Changchun, Jilin, China;Department of Pathology, Jilin Oil Field General Hospital, Songyuan, Jilin, China

关键词: Breast invasive ductal carcinomas;    DNA methyltransferase 1;    Methyl-CpG binding protein 2;    Histone deacetylase 1;    Claudin-6;   

Others  :  808125
DOI  :  10.1186/1746-1596-7-33

 received in 2012-01-04, accepted in 2012-03-29,  发布年份 2012

【 摘 要 】

Background

Claudin-6 is a candidate tumor suppressor gene in breast cancer, and has been shown to be regulated by DNA methylation and histone modification in breast cancer lines. However, the expression of claudin-6 in breast invasive ductal carcinomas and correlation with clinical behavior or expression of other markers is unclear. We considered that the expression pattern of claudin-6 might be related to the expression of DNA methylation associated proteins (methyl-CpG binding protein 2 (MeCP2) and DNA methyltransferase 1 (DNMT1)) and histone modification associated proteins (histone deacetylase 1 (HDAC1), acetyl-histone H3 (H3Ac) and acetyl- histone H4 (H4Ac)).

Methods

We have investigated the expression of claudin-6, MeCP2, HDAC1, H3Ac and H4Ac in 100 breast invasive ductal carcinoma tissues and 22 mammary gland fibroadenoma tissues using immunohistochemistry.

Results

Claudin-6 protein expression was reduced in breast invasive ductal carcinomas (P < 0.001). In contrast, expression of MeCP2 (P < 0.001), DNMT1 (P = 0.001), HDAC1 (P < 0.001) and H3Ac (P = 0.004) expressions was increased. Claudin-6 expression was inversely correlated with lymph node metastasis (P = 0.021). Increased expression of HDAC1 was correlated with histological grade (P < 0.001), age (P = 0.004), clinical stage (P = 0.007) and lymph node metastasis (P = 0.001). H3Ac expression was associated with tumor size (P = 0.044) and clinical stage of cancers (P = 0.034). MeCP2, DNMT1 and H4Ac expression levels did not correlate with any of the tested clinicopathological parameters (P > 0.05). We identified a positive correlation between MeCP2 protein expression and H3Ac and H4Ac protein expression.

Conclusions

Our results show that claudin-6 protein is significantly down-regulated in breast invasive ductal carcinomas and is an important correlate with lymphatic metastasis, but claudin-6 down-regulation was not correlated with upregulation of the methylation associated proteins (MeCP2, DNMT1) or histone modification associated proteins (HDAC1, H3Ac, H4Ac). Interestingly, the expression of MeCP2 was positively correlated with the expression of H3Ac and H3Ac protein expression was positively correlated with the expression of H4Ac inbreast invasive ductal carcinoma

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4549669866581452 webcite

【 授权许可】

   
2012 Xu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Warner E: Clinical practice. Breast-cancer screening. N Engl J Med 2011, 365(11):1025-1032.
• [2]Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22(13):2021-2033.
• [3]Escudero-Esparza A, Jiang WG, Martin TA: The Claudin family and its role in cancer and metastasis. Front Biosci 2011, 16:1069-1083.
• [4]Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, Tamura A, Igarashi M, Endo T, Takeuchi K, et al.: Predicted expansion of the claudin multigene family. FEBS Lett 2011, 585(4):606-612.
• [5]Turksen K, Troy TC: Junctions gone bad: claudins and loss of the barrier in cancer. Biochim Biophys Acta 2011, 1816(1):73-79.
• [6]Turksen K, Troy TC: Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn 2001, 222(2):292-300.
• [7]Findley MK, Koval M: Regulation and roles for claudin-family tight junction proteins. IUBMB Life 2009, 61(4):431-437.
• [8]Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH, Song YS, Marquez VE, Nephew KP, Shin YK: Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010, 31(6):974-983.
• [9]Honda H, Pazin MJ, Ji H, Wernyj RP, Morin PJ: Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 2006, 281(30):21433-21444.
• [10]Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
• [11]Veeck J, Esteller M: Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010, 15(1):5-17.
• [12]Yang X, Yan L, Davidson NE: DNA methylation in breast cancer. Endocr Relat Cancer 2001, 8(2):115-127.
• [13]Kouzarides T: Chromatin modifications and their function. Cell 2007, 128(4):693-705.
• [14]Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435(7046):1262-1266.
• [15]Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, et al.: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002, 21(11):2672-2681.
• [16]Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41(3A):154-161.
• [17]Yafang L, Qiong W, Yue R, Xiaoming X, Lina Y, Mingzi Z, Ting Z, Yulin L, Chengshi Q: Role of Estrogen Receptor-alpha in the Regulation of Claudin-6 Expression in Breast Cancer Cells. J Breast Cancer 2011, 14(1):20-27.
• [18]Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kosuge T, Hirohashi S: Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 2005, 96(7):403-408.
• [19]Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003, 105(4):527-532.
• [20]Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y: Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007, 72(1-2):69-74.
• [21]Quan C, Lu SJ: Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays. Carcinogenesis 2003, 24(10):1593-1599.
• [22]Wu Q, Liu Y, Ren Y, Xu X, Yu L, Li Y, Quan C: Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur J Cancer Prev 2010, 19(3):186-194.
• [23]Osanai M, Murata M, Chiba H, Kojima T, Sawada N: Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci 2007, 98(10):1557-1562.
• [24]Bird A: The methyl-CpG-binding protein MeCP2 and neurological disease. Biochem Soc Trans 2008, 36(Pt 4):575-583.
• [25]Hua X, Yu L, Huang X, Liao Z, Xian Q: Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn Pathol 2011, 6:111. BioMed Central Full Text
• [26]Antonelli M, Hasselblatt M, Haberler C, Di Giannatale A, Garre ML, Donofrio V, Lauriola L, Ridola V, Arcella A, Fruhwald M, et al.: Claudin-6 is of limited sensitivity and specificity for the diagnosis of atypical teratoid/rhabdoid tumors. Brain Pathol 2011, 21(5):558-563.
• [27]Ouban A, Ahmed AA: Claudins in human cancer: a review. Histol Histopathol 2010, 25(1):83-90.
• [28]Schneppenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, Kreuz M, Leuschner I, Martin Subero JI, Obser T, et al.: Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010, 86(2):279-284.
• [29]Brenner C, Fuks F: DNA methyltransferases: facts, clues, mysteries. Curr Top Microbiol Immunol 2006, 301:45-66.
• [30]Bogdanovic O, Veenstra GJ: DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 2009, 118(5):549-565.
• [31]Wojdacz TK, Thestrup BB, Overgaard J, Hansen LL: Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events. Diagn Pathol 2011, 6:116. BioMed Central Full Text
• [32]Muller HM, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, Muller-Holzner E, Marth C, Widschwendter M: MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer 2003, 89(10):1934-1939.
• [33]Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88(4):471-481.
• [34]Magdinier F, Billard LM, Wittmann G, Frappart L, Benchaib M, Lenoir GM, Guerin JF, Dante R: Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J 2000, 14(11):1585-1594.
• [35]Wischnewski F, Friese O, Pantel K, Schwarzenbach H: Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 2007, 5(7):749-759.
• [36]Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19(2):187-191.
• [37]Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393(6683):386-389.
• [38]Segre CV, Chiocca S: Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2010, 2011:690848.
• [39]Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008, 9(2):139-148.
• [40]Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14(6):1669-1677.
• [41]Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M: Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36(3):e1-e9.
• [42]Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J: Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90(1):15-23.